{"denoms":[{"counts":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"26"},{"groupId":"BG006","value":"13"},{"groupId":"BG007","value":"53"},{"groupId":"BG008","value":"47"},{"groupId":"BG009","value":"28"},{"groupId":"BG010","value":"14"},{"groupId":"BG011","value":"17"},{"groupId":"BG012","value":"226"}],"units":"Participants"}],"groups":[{"description":"Participants received a single dose of 7.5 mg CC-223 on Day -1, then daily dosing of 7.5 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG000","title":"Part A: CC-223 7.5 mg"},{"description":"Participants received a single dose of 15 mg CC-223 on Day -1, then daily dosing of 15 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG001","title":"Part A: CC-223 15 mg"},{"description":"Participants received a single dose of 30 mg CC-223 on Day -1, then daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG002","title":"Part A: CC-223 30 mg"},{"description":"Participants received a single dose of 45 mg CC-223 on Day -1, then daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG003","title":"Part A: CC-223 45 mg"},{"description":"Participants received a single dose of 60 mg CC-223 on Day -1, then daily dosing of 60 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG004","title":"Part A: CC-223 60 mg"},{"description":"Participants with NSCLC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG005","title":"Part B: Non-small Cell Lung Cancer (NSCLC)"},{"description":"Participants with GBM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG006","title":"Part B: Glioblastoma Multiforme (GBM)"},{"description":"Participants with HCC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG007","title":"Part B: Hepatocellular Carcinoma (HCC)"},{"description":"Participants with NET received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG008","title":"Part B: Neuroendocrine Tumor (NET)"},{"description":"Participants with DLBCL received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG009","title":"Part B: Diffuse Large B-cell Lymphoma (DLBCL)"},{"description":"Participants with MM received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG010","title":"Part B: Multiple Myeloma (MM)"},{"description":"Participants with HRPBC received CC-223 at a starting dose of 45 mg/day (reduced to 30 mg/day after protocol Amendment 9) orally once a day in 28-day cycles for as long as they derived benefit from treatment as judged by the investigator.","id":"BG011","title":"Part B: Hormone Receptor Positive Breast Cancer (HRPBC)"},{"description":"Total of all reporting groups","id":"BG012","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"comment":"Standard Deviation not calculable because data were only collected for 1 participant","groupId":"BG000","spread":"NA","value":"55.0"},{"groupId":"BG001","spread":"10.61","value":"54.5"},{"groupId":"BG002","spread":"11.57","value":"53.8"},{"groupId":"BG003","spread":"12.86","value":"46.0"},{"groupId":"BG004","spread":"11.65","value":"49.9"},{"groupId":"BG005","spread":"10.72","value":"62.8"},{"groupId":"BG006","spread":"9.46","value":"55.6"},{"groupId":"BG007","spread":"11.41","value":"60.0"},{"groupId":"BG008","spread":"9.87","value":"62.6"},{"groupId":"BG009","spread":"14.51","value":"53.9"},{"groupId":"BG010","spread":"10.00","value":"60.4"},{"groupId":"BG011","spread":"7.79","value":"53.9"},{"groupId":"BG012","spread":"11.77","value":"58.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"28"},{"groupId":"BG009","value":"11"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"17"},{"groupId":"BG012","value":"108"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"43"},{"groupId":"BG008","value":"19"},{"groupId":"BG009","value":"17"},{"groupId":"BG010","value":"8"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"118"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"2"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"16"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"44"},{"groupId":"BG008","value":"45"},{"groupId":"BG009","value":"22"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"11"},{"groupId":"BG012","value":"188"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"22"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"20"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"0"},{"groupId":"BG012","value":"9"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"12"},{"groupId":"BG007","value":"31"},{"groupId":"BG008","value":"43"},{"groupId":"BG009","value":"24"},{"groupId":"BG010","value":"8"},{"groupId":"BG011","value":"10"},{"groupId":"BG012","value":"171"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"},{"groupId":"BG012","value":"4"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"6"},{"groupId":"BG011","value":"5"},{"groupId":"BG012","value":"22"}],"title":"Missing"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race","unitOfMeasure":"Participants"}],"populationDescription":"All treated participants"}